Overview Latest Regional Industry Featured Multimedia Other Languages Public Company News
All APAC Global
All APAC Global
All APAC Global
All APAC Global
OliPass Discloses Painful but Hilarious Clinical Findings from a Phase 2a Trial in OA Patients with Nav1.7 Selective Inhibitor OLP-1002 2023-11-13 22:00
Nav1.7 Selective Inhibitor OLP-1002 Shows Strong Efficacy and Long Therapeutic Duration according to Interim Findings from a Phase 2a Study in OA Patients 2023-03-16 21:00
OliPass Moves Forward to Second Stage of Phase 2a Trial for Pain Killer OLP-1002 2022-07-18 20:00
OliPass Announces Commencement of Dosing in Phase 2a Trial for Pain Killer OLP-1002 2022-02-18 23:00
SCN9A Antisense Pain Killer OLP-1002 Moves into Phase 2a Stage 2021-10-25 20:30
OliPass Expands Scientific Advisory Board by Inviting Experts in Pain To Bolster Phase 2 Clinical Trial Design and Management 2021-06-10 21:00
OliPass Announces Formation of Scientific Advisory Board of Pioneers in Sodium Ion Channellopathy and Pain 2020-11-24 22:00
1